Lidocaine for Ehlers-Danlos Syndrome

Recruiting in Palo Alto (17 mi)

Overseen bySatish R Raj, MD MSCI

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: University of Calgary

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is investigating how well numbing medicines work for people with EDS. These patients often say these medicines don't work properly for them. The study aims to find out if the problem is that the medicine doesn't work, stops working too soon, or takes too long to start.

Eligibility Criteria

This trial is for individuals with genetically confirmed non-hypermobile Ehlers-Danlos Syndrome (EDS), those clinically diagnosed with hypermobile EDS, and healthy volunteers without EDS. Participants must be able to give informed consent. Those allergic to Lidocaine cannot join.

Inclusion Criteria

You are a healthy participant without Ehlers-Danlos syndrome.

I have a genetic test confirming I have a type of EDS that is not hypermobile.

People with clinically diagnosed hypermobile Ehlers-Danlos syndrome based on 2017 criteria.

See 1 more

Exclusion Criteria

I am unable to understand and give consent for treatment.

You have a known allergy to lidocaine.

Treatment Details

Interventions

0.9% Sodium Chloride Injection (Other)
Bupivacaine Injection 0.5% (Local Anesthetic)
Lidocaine Injection 2% (Local Anesthetic)

Trial OverviewThe study aims to objectively measure local anesthetic resistance in people with EDS compared to healthy individuals by using a common saltwater solution (0.9% Sodium Chloride) as a control and Lidocaine Injection 2% as the test intervention.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Receiving Local Anesthetic InjectionExperimental Treatment2 Interventions

Patients meeting the diagnostic criteria (2017) for Ehlers-Danlos Syndrome Healthy control volunteers who do not meet the criteria for Ehlers-Danlos Syndrome